Magnolia’s Post

Why do drug developers turn to Sanquin PBS when faced with demanding cells? Just because a cell is delicate to work with doesn’t mean that it should be excluded from quality, safety, or efficacy controls during drug development. Through its vast experience and an optimized workflow, Sanquin PBS can study all phenotypic and functional aspects of difficult-to-handle blood cells including phagocytosis, degranulation, NETosis, migration, cytokine release, and apoptosis.  Read more in our blood story: Why do clients turn to Sanquin PBS when faced with difficult cells? - https://lnkd.in/eMdQ7qWG #drugdevelopment #pharma #biotech #bioanalysis #immunomonitoring 

Estimates suggest that ~350m people live with #rarediseases globally. On #RareDiseaseDay find out why it’s not so rare to have a #raredisease and how we can innovate to overcome the challenges of developing new treatments at https://bit.ly/3kkFQUE. #clinicaltrials #biotech #pharma #biopharma #orphandisease #orphandiseases

🧬💊 Discover some common misconceptions about the pharma and biotech industry that might surprise you! 🤝  In my conversations, I realise that many people outside our industry still hold misconceptions. So, I’ve put together a collection of the most popular ones. 📜 Download a free slide deck to uncover the truth. If you want Part 2, please let me know by commenting on this post. I will then send you a pdf. #Biotech #Pharma #IndustryInsights #MythBusting #CDMO #misconceptions

Time and money are precious—save both with MAbSilico! 💰 Skip the back-and-forth optimization of hits and start immediately with lead candidates ready for development. Maximize efficiency and minimize costs in your antibody discovery journey. 🌐 mabsilico.com #DrugDesign #DrugDiscovery #BioTechs #Pharma #Insilico

The hematology competitive intelligence team at a prominent pharma and biotech company 🧬🔬 had limited resources and internal bandwidth, causing them to miss critical competitive and industry updates. Evalueserve was asked to assemble a specialized team and provide a custom competitive intelligence solution. 🌟 Read the case study to learn how our approach delivered critical information almost twice as fast as before:  https://hubs.ly/Q02hgGb50. 🌟 #CompetitiveIntelligence #MarketIntelligence #Pharma #Biotech

We're getting questions on what BioCentury Inc. is hearing about the Biosecure Act (and similar bills), which could restrict U.S. biopharma access to Chinese CDMOs (e.g., WuXi AppTec, WuXi Biologics) and genomics companies. For those looking for answers, we have posted two (free) resources to check out: ➢ BioCentury industry survey results (March 21) on the likely impact of the bills on drug development and U.S. biotech: https://lnkd.in/ddBzRwNi ➢ Discussion of the survey results on the BioCentury This Week podcast (March 25), including commentary from my colleagues Simone Fishburn, Steve Usdin and Jeff Cranmer: https://lnkd.in/dxHyp96n We will post more, as we hear more. Bookmark this Hot Topics page for future posts: https://lnkd.in/denr92vJ #drugdevelopment #biopharma #biotech #pharma

If you're in San Antonio this week attending the Tandem meetings, let's connect and discuss the latest breakthroughs in #celltherapy and how our new digital solution helps to improve patient access to advanced therapies! DM me at Christopher Leidli 🧬 #networking #advancedtherapies #genetherapies #pharma #biotech #venturecapital

We all know the importance of Sample Management. Why not join #Avantor next week at our 4th EU Sample Management Symposium?! See below for more details and the links to register - see you there !! #Pharma #biotech #Avantorsetsscienceinmotion #SLAS2024

One of the key advantages of MAbSilico's approach lies in its ability to rapidly sift through vast libraries of antibodies, characterizing their properties and identifying promising candidates in a fraction of the time required by traditional methods. Learn more today! 🌐 mabsilico.com #BioTechs #Pharma #Insilico

Attended the PBSS workshop on Human #MassBalance and #MetaboliteProfiling Studies in San Francisco yesterday. Interesting talks by experts from Industry and #FDA. The workshop perfectly covered the strategies, technical approaches (including microtracer AMS), regulatory guidance, applications and case studies. The event was organized by Chandra Prakash, chaired by Shichang Miao and ended with a vibrant Panel Discussion. Thanks to all the speakers: Chandra Prakash (Agios Pharmaceuticals), Bernard Murray (Gilead Sciences), Shuai Wang (Genentech), Ronald Kong (PTC Therapeutics, Inc.), Grace Yan Danielsen (FDA), Ryan Takahashi (Stealth NewCo) and Raman Sharma (Pfizer). #TNO #Peregrion #DMPK #ADME #Bioavailability #MetID #Pharmacokinetics #Bioanalysis #DrugDevelopment.